Form 4: ClearPoint Neuro CFO Danilo D'Alessandro Reports Acquisition of Restricted Stock Units
SEC Form 4 Filing
ClearPoint Neuro's CFO, Danilo D'Alessandro, reports the acquisition of 81,566 restricted stock units.
Summary
- Danilo D'Alessandro, CFO of ClearPoint Neuro, Inc., filed a Form 4 with the SEC.
- The filing reports the acquisition of 81,566 restricted stock units on May 20, 2024.
- These restricted stock units represent a contingent right to receive one share of ClearPoint Neuro common stock each.
- The restricted stock units vest in three tranches: 20% on March 12, 2025, 40% on March 12, 2026, and 40% on March 12, 2027.
Sentiment
Score: 6
Explanation: The document is a standard SEC filing related to executive compensation, which is neutral in sentiment.
Positives
- The acquisition of restricted stock units by the CFO aligns his interests with those of the shareholders.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders.
Stakeholder Impact
- The granting of restricted stock units can incentivize management to improve company performance, potentially benefiting shareholders.
Key Dates
| Date | Description |
|---|---|
| 05/20/2024 | Date of transaction: Acquisition of restricted stock units |
| 03/12/2025 | 20% of restricted stock units vest |
| 03/12/2026 | 40% of restricted stock units vest |
| 03/12/2027 | 40% of restricted stock units vest |
| 05/22/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.